Atogepant

🧮 Dose calculator

Migraine prophylaxis · Regimen source: FDA Qulipta · 2.1

• • Strong CYP3A4 inhibitors: 10 mg; strong CYP3A4 inducers: 60 mg (not recommended in chronic migraine). Other interactions per Table 1. FDA Qulipta · 2.2, Table 1

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Qulipta · 8.1

  “Risk Summary There are no adequate data on the developmental risk associated with the use of QULIPTA in pregnant women.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Qulipta · 8.2

  “Risk Summary Data from a lactation study in twelve healthy adult females indicate that atogepant is excreted in breast milk in low amounts.”

• 👶 ChildrenSafety not established

  Label: safety and effectiveness in children have not been established. FDA Qulipta · 8.4

  “Safety and effectiveness in pediatric patients have not been established.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Qulipta · 8.5

  “In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.